<DOC>
	<DOCNO>NCT02785770</DOCNO>
	<brief_summary>This study design ascertain effect PF-04447943 QT interval healthy adult subject . This conducted part standard drug development .</brief_summary>
	<brief_title>A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Healthy female subject non childbearing potential and/or healthy male subject , age 18 55 year . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . History cerebrovascular accident , transient ischemic attack ( TIA ) , traumatic brain injury . History seizure history physical examination finding ( eg localizing sign neurologic examination ) suggestive structural central nervous system ( CNS ) abnormality may place patient increase risk seizure . History orthostatic blood pressure change clinically significant orthostatic symptom . Self report history risk factor QT prolongation torsades de pointes ( eg , organic heart disease , congestive heart failure , hypokalemia , hypomagnesaemia , congenital long QT syndrome , myocardial ischemia infarction ) , congenital deafness , family history sudden death , family history long QT syndrome .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>